HARVEY SHAPIRO: Open Payments
NPI 1578577961 · FORT MYERS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,268 in 63 payments from 13 companies in 2025. Trend: 2023 $238 · 2024 $442 · 2025 $1,268
Food & beverage: $1,268
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $254 |
| Otsuka America Pharmaceutical, Inc. | 8 | $239 |
| ABBVIE INC. | 10 | $190 |
| Lundbeck LLC | 11 | $181 |
| Axsome Therapeutics, Inc. | 8 | $164 |
| Alkermes, Inc. | 3 | $67 |
| Neurocrine BioSciences, Inc. | 1 | $34 |
| Supernus Pharmaceuticals, Inc. | 2 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Vanda Pharmaceuticals Inc. | 1 | $26 |
Products named: REXULTI, CAPLYTA, VRAYLAR, Auvelity, INGREZZA, Qelbree, TRINTELLIX, FANAPT.
Industry payments across FL — which companies pay providers there.
